On Friday, The dollar climbed and Treasuries dropped down after shareholders factored in the possibility that the Fed could put into practice its first rate hike in almost a decade as soon as June. The prospects of higher interest rates sent stocks tumbling. The market logged its worst day in two months.
Insights about U.S. Stocks that landed in the Active-Zone during Friday’s trade, are depicted underneath:
Medtronic PLC (NYSE:MDT)’s shares dipped -2.57%, and traded at $76.48. The Stock is active as 7.05M shares changed hands versus its average volume of 9.45M shares.
Medtronic plc (MDT), the world`s leading medical technology corporation, declared it will take part in the Barclays Global Healthcare Conference in Miami. Gary Ellis, executive vice president and chief financial officer of Medtronic, will make a presentation about Medtronic on Wednesday, March 11, 2015, starting at 9:30a.m. EDT (8:30a.m. CDT).
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is the global leader in medical technology - alleviating pain, restoring health and extending life for millions of people around the world.
Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX), raised 4.46%, and traded at $1.17. The Stock is active as 7.05M shares changed hands versus its average volume of 1.81M shares.
Lexicon Pharmaceuticals, Inc. (LXRX), a biopharmaceutical corporation focused on developing breakthrough treatments for human disease, updated its drug development progress and stated financial results for the three months and year ended December 31, 2014.
In October 2014, Lexicon accomplished a partnership contract with Ipsen Pharma SAS for the commercialization of telotristat etiprate, with a focus on carcinoid syndrome, in markets outside the United States, Canada and Japan. Under the contract, Lexicon is eligible to receive up to about $145 million in aggregate upfront and milestone payments, counting an upfront payment of $23 million. In addition, Lexicon is entitled to receive royalties on net sales of telotristat etiprate by Ipsen.
Also in the fourth quarter of 2014, Lexicon accomplished concurrent debt and equity financings that resulted in gross proceeds of $293.4 million. After fees and offering expenses, the financings resulted in net proceeds of $286.0 million and are reflected in the corporation’s financial results as of December 31, 2014. In the aggregate, the financings comprised of the issuance of about 204.9 million shares of ordinary stock, with gross proceeds of $205.9 million, and $87.5 million in aggregate principal amount of 5.25% convertible senior notes due 2021.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical corporation, focuses on the development of treatments for human disease. Its drug development programs comprise LX4211, an orally-delivered small molecule compound that has accomplished two Phase II clinical trials for the treatment of type 2 diabetes patients, in addition to an additional clinical trial for the treatment of type 2 diabetes patients with renal impairment; and concluding a Phase II clinical trial for the treatment of type 1 diabetes patients.
Mosaic Co (NYSE:MOS), dropped -2.78%, and traded at $49.03. The Stock is active as 7.00M shares changed hands versus its average volume of 3.59M shares.
The Mosaic Company (MOS), declared it will hold an Analyst Day on Tuesday, March 31, 2015. The meeting, which will be held at Streamsong Resort in Tampa, Florida, will start at 7:30 a.m. and is planned to end at about 11:00 a.m. Eastern Daylight Time.
Jim Prokopanko, Mosaic’s President and Chief Executive Officer, will host the meeting and provide an update on Mosaic’s progress against planned objectives and talk about drivers of long term value creation. Joc O’Rourke, Executive Vice President and Chief Operating Officer, will review progress against operational targets and talk about Esterhazy K3 acceleration plans. Rick McLellan, Senior Vice President of Commercial, will provide an overview of distribution capabilities and competitive positioning. Rich Mack, Executive Vice President and Chief Financial Officer, will review Mosaic’s financial road map and capital allocation priorities.
The Mosaic Corporation is one of the world’s leading producers and marketers of concentrated phosphate and potash crop nutrients. Mosaic is a single source provider of phosphate and potash fertilizers and feed ingredients for the global agriculture industry.
CSX Corporation (NYSE:CSX), dwindled -0.59%, and traded at $33.68. The Stock is active as 6.93M shares changed hands versus its average volume of 6.66M shares.
CSX Corp. (CSX), declared that a portion of the Ocala / Marion County Commerce Park in Ocala, Florida has been designated a CSX Select Site. Select Sites are properties identified and vetted as capable locations for future manufacturing facilities along the CSX network. These sites can be developed quickly since standard land use issues and comprehensive due diligence items have already been addressed.
“Through the Select Site program, we can significantly reduce the time it takes for companies to evaluate a competitive site, and ultimately construct their facility and bring products to market,” said Clark Robertson, assistant vice president, regional development at CSX.
CSX introduced the Select Site program in 2012 to better serve new or existing customers on its network. CSX partnered with The Austin Corporation, a nationally-known site selection consulting firm, to screen candidate sites and assist communities with the application and certification process.
The Ocala / Marion County Commerce Park is the first site in Florida to be designated as a CSX Select Site.
CSX, based in Jacksonville, Florida, is a premier transportation corporation. It provides rail, intermodal and rail-to-truck transload services and solutions to customers across a broad array of markets, counting energy, industrial, construction, agricultural, and consumer products.
